ImmunityBio’s Fortunes Rise with Asian Approval

The company had already benefited from a degree of encouragement, stemming from the recent revision of the National Comprehensive Cancer Network’s clinical guidelines. The inclusion of Anktiva®, in combination with Bacillus Calmette-Guérin, as a suitable treatment for certain bladder cancers unresponsive to simpler remedies, had provided a welcome boost. Now, it appears Macau’s authorities perceive a similar merit in this therapeutic alliance, granting approval for the very same patient cohort. One cannot help but observe that a favourable verdict, even in a smaller sphere, possesses a peculiar power to inspire confidence.







